Etelcalcetide Hydrochloride

DRUG2 trials

Sponsors

Division of Nephrology, Department of Medicine, Kurume University, Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Conditions

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on HemodialysisSecondary hyperparathyroidism

Phase 2

MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease

CompletedNCT06690242

Shaanxi Micot Pharmaceutical Technology Co., Ltd.Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Start: 2024-11-04End: 2025-08-30Updated: 2026-07-22

Unknown Phase

The relationship of the effective dose and safety of cinacalcet hydrochloride and etelcalcetide hydrochloride in the Japanese patients with secondary hyperparathyroidism receiving hemodialysis, when switching cinacalcet hydrochloride to etelcalcetide hydrochloride.

Active, not recruitingJPRN-UMIN000027637

Division of Nephrology, Department of Medicine, Kurume UniversitySecondary hyperparathyroidism

Start: 2017-06-05Target: 120Updated: 2026-06-29